Thomas Köhnke

Medicine · Health Sciences

23h-index2.4kcitations197works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(59), Cancer Research and Treatments(58), Virus-based gene therapy research(56), CAR-T cell therapy research(46), RNA Interference and Gene Delivery(41)

Publications197 total

Supplementary Table S1-S4 from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
2026Open Access
Data from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
2026Open Access
Supplementary Figure S1-S8 from Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML
2026Open Access
Supplemental Figure S4 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Figure S9 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Figure S3 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Figure S6 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Table 1 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Figure S7 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Figure S1 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Figure S8 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplementary Table 1 from Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability
2025Open Access
Supplemental Figure S2 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Figure S5 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
Supplemental Figure S10 from Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy
2025Open Access
DNMT3A R882H Is Not Required for Disease Maintenance in Primary Human AML but Is Associated with Increased Leukemia Stem Cell Frequency
Cancer Discovery·2025Open Access
Human HSPCs CRISPR-engineered to endogenously express oncogenic NRAS generate a transplantable lethal myeloid malignancy targetable with novel RAS therapeutics
Blood·2025Open Access
Sensitive detection of novel structural variants and 3D chromosome conformation reveals likely novel drivers including enhancer hijacking in AML
Blood·2025Open Access
Inhibition of DOCK1 prevents the clonal expansion of high-risk TP53-mutant clonal hematopoiesis induced by genotoxic stressors.
Blood·2025· 1 citedOpen Access
1228 Immune escape through oncogene-mediated editing of the HLA-ligandome
Regular and Young Investigator Award Abstracts·2025Open Access
page 1 of 10Next →

Frequent Co-authors

Marion Subklewe(22), Ravindra Majeti(19), Karsten Spiekermann(16), Christina Krupka(15), Wolfgang Hiddemann(15), Felix S. Lichtenegger(14), Torben Altmann(9), Veit Bücklein(9), Klaus H. Metzeler(8), Yusuke Nakauchi(8), Michael Fiegl(7), Peter Kufer(6), Roman Kischel(6), Melissa Stafford(6), Amy C. Fan(6), Armon Azizi(6), Frauke M. Schnorfeil(5), Stephanie Schneider(5), Gerhard Zugmaier(5), Jan Braess(5)